¶ Neuroinflammation and Microglia Pathway
Neuroinflammation And Microglia Pathway represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
Neuroinflammation is the inflammatory response within the central nervous system (CNS), primarily mediated by microglia and astrocytes. While acute neuroinflammation serves as a protective response to injury or infection, chronic neuroinflammation becomes a pathological driver of neurodegenerative processes in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurological disorders.
The neuroinflammation pathway represents a critical intersection between the innate immune system and neurodegeneration. Microglia, the resident macrophages of the brain, adopt disease-associated phenotypes that can both protect and harm neurons depending on their activation state.
Microglia perform essential functions in the healthy brain:
| Function |
Description |
Mechanism |
| Surveillance |
Continuous monitoring of the brain environment |
Process extension and retraction |
| Synaptic pruning |
Elimination of excess synapses during development |
Complement-mediated phagocytosis (C1q, C3) |
| Phagocytosis |
Clearance of cellular debris and pathogens |
Receptor-mediated engulfment |
| Neurotrophic support |
Release of brain-derived neurotrophic factor (BDNF) |
Trophic factor secretion |
| Wound healing |
Response to injury and tissue repair |
Cytokine and growth factor release |
Microglia can adopt multiple activation phenotypes, broadly categorized as:
M1 (Classical Activation)
- Triggered by: LPS, IFN-γ, Aβ, TNF-α
- Markers: CD16, CD32, CD86, iNOS
- Products: Pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-12), reactive oxygen species (ROS), reactive nitrogen species (RNS)
- Function: Pro-inflammatory, cytotoxic
M2 (Alternative Activation)
- Triggered by: IL-4, IL-13, IL-10, glucocorticoids
- Markers: CD206 (mannose receptor), Arg1, YM1, Fizz1
- Products: Anti-inflammatory cytokines (IL-10, TGF-β), neurotrophic factors (BDNF, IGF-1)
- Function: Anti-inflammatory, tissue repair, wound healing
Disease-Associated Microglia (DAM)
- TREM2-dependent activation pathway
- Characterized by upregulated genes involved in lipid metabolism, phagocytosis, and lysosomal function
- Initially protective but can become dysregulated in chronic disease states
Microglia express numerous PRRs that detect endogenous danger signals:
| Receptor |
Ligands |
Signaling Pathway |
Disease Association |
| TLR4 |
Aβ, HMGB1, LPS |
MyD88/TRIF |
AD, PD |
| TLR9 |
DNA, Aβ aggregates |
MyD88 |
AD, MS |
| RAGE |
Aβ, HMGB1, S100 proteins |
NF-κB, MAPK |
AD, PD, ALS |
| NLRP3 |
Aβ, MSU, ATP, α-synuclein |
ASC, caspase-1 |
AD, PD, Gout |
The NLRP3 inflammasome is a key driver of neuroinflammation:
flowchart TD
A[Aβ/α-synuclein] --> B[TLR4/ TLR2 Activation]
B --> C[NLRP3 Inflammasome Assembly]
C --> D[ASC Polymerization]
D --> E[Pro-caspase-1 Activation]
E --> F[Caspase-1 Auto-cleavage]
F --> G[IL-1β and IL-18 Maturation]
G --> H[Pro-inflammatory Cytokine Release]
H --> I[Pyroptosis Cell Death]
H --> J[Chronic Neuroinflammation]
NF-κB is a master regulator of inflammatory gene expression:
- PRR activation → IKK complex activation
- IκB degradation → NF-κB translocation to nucleus
- Pro-inflammatory gene transcription:
- Cytokines: TNF-α, IL-1β, IL-6, IL-8
- Chemokines: CCL2, CXCL10
- Enzymes: COX-2, iNOS
- Adhesion molecules: ICAM-1, VCAM-1
Aβ plaques directly activate microglia through multiple mechanisms:
- TLR4/CD14 complex recognizes Aβ fibrils
- NLRP3 inflammasome is activated by Aβ
- TREM2 signaling modulates microglial response to Aβ
- CD33 regulates Aβ phagocytosis (protective variant reduces AD risk)
The relationship between tau pathology and neuroinflammation is bidirectional:
- Inflammation drives tau: IL-1β promotes tau phosphorylation via CDK5 and GSK3β
- Tau drives inflammation: Extracellular tau aggregates activate microglia
- Spread facilitation: Inflammation may promote tau propagation between neurons
¶ TREM2 and AD Risk
TREM2 variants significantly impact AD risk:
| Variant |
AD Risk |
Effect |
| R47H |
~3x increased |
Loss of phagocytic function |
| R62H |
~1.5x increased |
Reduced ligand binding |
| R62P |
~2x increased |
Impaired signaling |
| D87N |
Variable |
Partial loss of function |
TREM2 deficiency in mouse models results in:
- Reduced microglial clustering around plaques
- Increased plaque burden
- Impaired Aβ clearance
- Enhanced neuritic degeneration
α-Synuclein aggregates activate microglia through:
- TLR2/TLR4 recognition of extracellular α-synuclein
- NLRP3 inflammasome activation
- Pro-inflammatory cytokine release (TNF-α, IL-1β, IL-6)
- ROS production leading to oxidative stress
The substantia nigra pars compacta is particularly susceptible:
- High basal microglial density
- Neuromelanin as an endogenous trigger
- High iron content promoting oxidative stress
- Dopaminergic neuron sensitivity to inflammation
| Gene |
Variant |
Effect |
| GBA |
N370S |
Lysosomal dysfunction, increased inflammation |
| LRRK2 |
G2019S |
Enhanced microglial activation |
| SNCA |
Multiplications |
Increased α-synuclein, secondary inflammation |
ALS involves prominent neuroinflammation:
- Activated microglia surround motor neurons
- Astrocytes become reactive and lose supportive function
- NLRP3/ASC specks are found in ALS spinal cord
- C9orf72 mutations cause innate immune dysregulation
- Presymptomatic: Subtle microglial activation
- Early disease: Prominent microglial proliferation
- Late disease: Loss of anti-inflammatory (M2) markers, dominance of M1 phenotype
The complement system is heavily implicated in neurodegenerative diseases:
Classical Pathway Activation
- C1q binds to Aβ plaques and degenerating synapses
- Initiates cascade producing C3a, C5a (anaphylatoxins)
- Opsonizes targets for microglial phagocytosis
C1q and C3 mediate pathological synaptic elimination:
- C1q tags vulnerable synapses for elimination
- C3 activation recruits microglia
- Complement receptor 3 (CR3) mediates phagocytosis
- Result: Excessive synaptic loss in early AD
| Gene |
Variant |
Effect |
| CR1 |
rs6653641 |
Altered complement activation, increased AD risk |
| C1Q |
Various |
Synaptic elimination dysregulation |
| Target |
Approach |
Agent |
Development Stage |
| TNF-α |
Monoclonal antibodies |
Etanercept, Infliximab |
Phase II AD |
| IL-1β |
IL-1 receptor antagonist |
Anakinra |
Phase II AD |
| NLRP3 |
Small molecule inhibitors |
MCC950, Dazodalibep |
Phase I/II |
| COX-2 |
NSAIDs |
Celecoxib |
Failed (high-dose) |
| CSF1R |
Receptor antagonist |
PLX3397, BLZ945 |
Phase I |
- TREM2 agonists: Enhance microglial phagocytosis of Aβ
- TREM2 antibodies: May enhance function (clinical trials ongoing)
- CD33 blockade: Reduce inflammatory activation
- PPAR-γ agonists: Shift toward anti-inflammatory phenotype
- CSF1R antagonists: Reduce microglial numbers (controversial)
| Trial |
Target |
Intervention |
Status |
| NCT04592354 |
TREM2 |
AL002 (anti-TREM2 antibody) |
Phase II |
| NCT03981493 |
TNF-α |
Etanercept |
Phase II |
| NCT02780557 |
IL-1β |
Anakinra |
Phase II |
| NCT04053426 |
NLRP3 |
MCC950 |
Phase I |
| Marker |
Fluid |
Changes in Neurodegeneration |
| YKL-40 (chitinase-3-like 1) |
CSF, plasma |
Elevated in AD, PD |
| IL-6 |
CSF, plasma |
Elevated in AD, correlates with cognitive decline |
| TNF-α |
CSF, plasma |
Elevated in AD, PD, ALS |
| IL-1β |
CSF |
Elevated in AD, PD |
| C1q |
CSF |
Elevated, correlates with synaptic loss |
| GFAP |
Plasma |
Astrocyte activation marker, elevated in AD |
| sTREM2 |
CSF |
Dynamic changes in AD progression |
- PK11195 PET: TSPO binding to visualize microglial activation
- MBP PET: Myelin binding for demyelination assessment
- FEPET: Monoamine oxidase B binding for neuroinflammation
- TREM2 — Triggering receptor expressed on myeloid cells 2
- CD33 — Siglec receptor, AD risk gene
- IL1B — Interleukin-1 beta
- TNF — Tumor necrosis factor alpha
- Microglia — Brain resident immune cells
The study of Neuroinflammation And Microglia Pathway has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Microglia in Alzheimer's disease: role in neurodegeneration and therapeutic strategies (2023)
- Neuroinflammation and microglial activation in Parkinson's disease (2022)
- TREM2 and microglia: implications for neurodegenerative diseases (2021)
- Inflammatory cytokines in neurodegeneration (2020)
- NLRP3 inflammasome in neuroinflammation (2019)
- Microglial polarization and neuroinflammation (2018)
- Neuroinflammation mechanisms in ALS and FTD (2017)
- Targeting neuroinflammation for disease modification (2016)
- Heneka MT et al. (2015). Neuroinflammation in Alzheimer's disease. Lancet Neurol. 14(4):388-405
- Keren-Shaul H et al. (2017). A unique microglia type associated with Alzheimer's disease. Cell. 170(6):1276-1290
- Guerreiro R et al. (2013). TREM2 variants in Alzheimer's disease. N Engl J Med. 368(2):117-127
- Heneka MT et al. (2013). NLRP3 is activated in Alzheimer's disease and contributes to pathology. Nature. 493(7433):674-678
- Zhou R et al. (2011). A role for mitochondria in NLRP3 inflammasome activation. Nature. 469(7329):221-225
- Halle A et al. (2008). The NALP3 inflammasome is involved in the innate immune response to amyloid-β. Nat Immunol. 9(8):857-865
- Block ML, Hong JS (2005). Microglia and inflammation-mediated neurodegeneration. Prog Neurobiol. 76(2):77-98
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
15 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 38%